GERN Jun 2024 3.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

1.9000

-0.0400

(-2.06%)

At close: 11:34AM EDT

Loading interactive chart...

Simply Wall St.
Geron Corporation's (NASDAQ:GERN) large institutional owners must be happy as stock continues to impress, up 27% over the past week
Key Insights Institutions' substantial holdings in Geron implies that they have significant influence over the...
Zacks
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
Yahoo Finance Video
Geron stock pops on FDA approval for blood cancer drug
Shares of Geron (GERN) are trading higher Friday, propelled by the recent Food & Drug Administration (FDA) approval of the company's blood disorder drug, Rytelo. The treatment is for adults with low- to intermediate-1 risk of myelodysplastic syndromes, a type of cancer. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith